Biodexa Pharmaceuticals PLC Share Price Today: Live Updates & Key Insights

Biodexa Pharmaceuticals PLC share price today is $0.6922, up 2.11%. The stock opened at $0.68 against the previous close of $0.6861, with an intraday high of $0.7154 and low of $0.68.

Biodexa Pharmaceuticals PLC Share Price Chart

Biodexa Pharmaceuticals PLC

us-stock
To Invest in {{usstockname}}
us-stock

Biodexa Pharmaceuticals PLC Share Price Performance

$0.6922 0.0211(2.11%) BDRX at 23 Mar 2026 12:10 PM Biotechnology
Lowest Today 0.68
Highest Today 0.7154
Today’s Open 0.68
Prev. Close 0.6861
52 Week High 19.30
52 Week Low 0.68
Day’s Range: Low 0.68 High 0.7154
52-Week Range: Low 0.68 High 19.30
1 day return -
1 Week return -11.11
1 month return -40.0
3 month return -78.58
6 month return -89.47
1 year return -58.81
3 year return -99.37
5 year return -99.98
10 year return -

Biodexa Pharmaceuticals PLC Institutional Holdings

Biodexa Pharmaceuticals PLC Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Biodexa Pharmaceuticals PLC Fundamentals

Market Cap 0.59 M

PB Ratio 0.0377

PE Ratio 0.0

Enterprise Value -4.15 M

Total Assets 14.78 M

Volume 69522

Biodexa Pharmaceuticals PLC Company Financials

Annual Revenue FY23:381000 0.4M

Annual Profit FY23:-3686000 -3.7M

Annual Net worth FY23:-7079000 -7.1M

Quarterly Revenue Q2/2025:null 0.0M, Q2/2024:null 0.0M, Q1/2024:null 0.0M, Q4/2023:41500 0.0M, Q3/2023:41500 0.0M

Quarterly Profit Q2/2025:-1665000 -1.7M, Q2/2024:-2189000 -2.2M, Q1/2024:-1094500 -1.1M, Q4/2023:-1084000 -1.1M, Q3/2023:-1084000 -1.1M

Quarterly Net worth Q2/2025:-3806000 -3.8M, Q2/2024:-3308000 -3.3M, Q1/2024:-1654000 -1.7M, Q4/2023:-1755500 -1.8M, Q3/2023:-1755500 -1.8M

About Biodexa Pharmaceuticals PLC & investment objective

Company Information Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Organisation Biotechnology

Employees 13

Industry Biotechnology

CEO Mr. Stephen Anthony Stamp

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Biodexa Pharmaceuticals PLC FAQs

What is the share price of Biodexa Pharmaceuticals PLC today?

The current share price of Biodexa Pharmaceuticals PLC is $0.6922.

Can I buy Biodexa Pharmaceuticals PLC shares in India?

Yes, Indian investors can buy Biodexa Pharmaceuticals PLC shares by opening an international trading and demat account with Motilal Oswal.

How to buy Biodexa Pharmaceuticals PLC shares in India?

You can easily invest in Biodexa Pharmaceuticals PLC shares from India by:

Can I buy fractional shares of Biodexa Pharmaceuticals PLC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Biodexa Pharmaceuticals PLC?

Biodexa Pharmaceuticals PLC has a market cap of $0.59 M.

In which sector does Biodexa Pharmaceuticals PLC belong?

Biodexa Pharmaceuticals PLC operates in the Biotechnology sector.

What documents are required to invest in Biodexa Pharmaceuticals PLC stocks?

To invest, you typically need:

What is the PE and PB ratio of Biodexa Pharmaceuticals PLC?

The PE ratio of Biodexa Pharmaceuticals PLC is N/A and the PB ratio is 0.04.